Aspirin resistance in hemodialysis patients

Geara, Abdallah S.; Azzi, Nassif; Bassil, Claude; El‐Sayegh, Suzanne

doi:10.1007/s11255-010-9811-y

Cited by 6 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Geara et al found AR in 34.8% of the patients undergoing HD. 21 This is lower than our result, but this difference may result from differences in the study population and in the methods that were used to determine AR.…”

Section: Discussioncontrasting

confidence: 78%

Aspirin Resistance in Patients Undergoing Hemodialysis and Effect of Hemodialysis on Aspirin Resistance

Aksu

Oner

Çelik

et al. 2013

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

The aim of this study was to evaluate the prevalence of aspirin resistance (AR) in patients undergoing hemodialysis (HD) and to assess the effect of HD on the results of the Multiplate test. A total of 54 patients undergoing HD were included in this study. Blood samples were taken just before and after the HD session. To determine AR, we used Multiplate test. Platelet aggregation values of the study population were 363.01 ± 225.69 aggregation unit (AU) × minutes before and 375.33 ± 254.05 AU × minutes after the HD (P = .597). There was strong correlation between the values before and after HD (R = .755, P < .0001). The AR status was changed in 9 (16.6%) patients after HD. Agreement of AR status before and after HD was substantial (κ coefficient = .667, P < .0001). The prevalence of AR in patients undergoing HD seems higher than in most of the studied populations, and this study has shown that the AR statuses of a significant number of patients undergoing HD change after an HD session.

show abstract

Section: Discussioncontrasting

confidence: 78%

Aspirin Resistance in Patients Undergoing Hemodialysis and Effect of Hemodialysis on Aspirin Resistance

Aksu

Oner

Çelik

et al. 2013

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Aspirin and clopidogrel were not associated with an increased risk of bleeding in ESRD undergoing dialysis patients. Although previously reported data regarding the efficacy and safety of antiplatelet therapy in preventing thrombotic complications in ESRD patients undergoing dialysis are rather limited, >65% of IS patients in this study were treated with antiplatelet drugs after discharge and over the course of 11‐year follow‐up .…”

Section: Discussionmentioning

confidence: 98%

“…A previous study investigating use of antiplatelet drugs in patients with cardiovascular disease has indicated that the risk of mortality is decreased with aspirin and clopidogrel treatment (33). However, recent evidence has indicated that a higher prevalence of aspirin or clopidogrel resistance may decrease antiplatelet function in patients with CKD and ESRD (12,21,23). In fact, the mechanism of platelet aggregation is complex, and it is even more so in patients with IS, cardiovascular disease, and ESRD.…”

Section: Discussionmentioning

confidence: 99%

“…Because of the decreased renal function in ESRD patients undergoing dialysis, an evaluation of the effectiveness and safety of these substances is difficult in them. Recent studies have shown a 30–40% prevalence of aspirin or clopidogrel resistance in these patients compared with patients without CKD . Thus, the protective effect of aspirin and clopidogrel in ESRD patients with vascular disease receiving dialysis may be decreased .…”

Section: Introductionmentioning

confidence: 99%

“…Recent studies have shown a 30–40% prevalence of aspirin or clopidogrel resistance in these patients compared with patients without CKD . Thus, the protective effect of aspirin and clopidogrel in ESRD patients with vascular disease receiving dialysis may be decreased . There are limited randomized controlled trials that have evaluated the efficacy and safety of aspirin or clopidogrel in terms of decreasing the risk of readmission for IS .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and Safety of Antiplatelet in Stroke Patients with End-Stage Renal Disease Undergoing Dialysis

Lee

Lai

et al. 2014

International Journal of Stroke

View full text Add to dashboard Cite

show abstract

Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events

Kim

Becker

2016

J Thromb Thrombolysis

View full text Add to dashboard Cite

Aspirin has been a cornerstone of cardiovascular disease prevention since the late 1980s. Despite the popularity of aspirin and its wide use, the proper dosing and frequency of aspirin has yet to be determined. Early aspirin trials focused on its utility in broad target populations, but this strategy did not magnify the benefit of aspirin, and rather increased the complication rate. We have learned from previous studies that laboratory and clinical response to aspirin therapy in patients with different conditions and settings are diverse. This difference in aspirin response necessitates a personalized, tailored aspirin therapy. We aim to perform a comprehensive review of the current evidence surrounding aspirin responsiveness in several distinct patient populations and the rationale of different aspirin frequency and dosing strategies. Our conclusions call for future studies to determine individualized aspirin strategies to maximize the benefit and minimize the risk of aspirin.

show abstract

Aspirin resistance in hemodialysis patients

Cited by 6 publications

References 15 publications

Aspirin Resistance in Patients Undergoing Hemodialysis and Effect of Hemodialysis on Aspirin Resistance

Aspirin Resistance in Patients Undergoing Hemodialysis and Effect of Hemodialysis on Aspirin Resistance

Effectiveness and Safety of Antiplatelet in Stroke Patients with End-Stage Renal Disease Undergoing Dialysis

Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events

Contact Info

Product

Resources

About